Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 24.20 | 26.14 | 30.30 | 22.40 | 28.18 | 30.10 | 38.24 | 23.58 | 34.00 | 30.10 | 27.20 | 20.72 |
| Expenses | 26.16 | 27.19 | 26.14 | 18.69 | 24.81 | 25.10 | 30.06 | 21.05 | 31.48 | 23.54 | 24.54 | 18.37 |
| Operating Profit | -1.96 | -1.05 | 4.16 | 3.71 | 3.37 | 5.00 | 8.18 | 2.53 | 2.52 | 6.56 | 2.66 | 2.35 |
| OPM % | -8.10% | -4.02% | 13.73% | 16.56% | 11.96% | 16.61% | 21.39% | 10.73% | 7.41% | 21.79% | 9.78% | 11.34% |
| Other Income | 0.64 | 0.58 | 0.30 | 0.08 | 0.37 | 0.42 | 0.44 | 0.85 | -0.33 | 0.10 | 1.01 | 0.08 |
| Interest | 1.12 | 1.31 | 1.34 | 1.11 | 1.04 | 1.01 | 1.40 | 1.75 | 0.27 | 0.75 | 0.75 | 0.83 |
| Depreciation | 0.82 | 0.82 | 0.82 | 0.90 | 0.79 | 0.82 | 0.88 | 0.94 | 0.97 | 0.85 | 1.16 | 1.11 |
| Profit before tax | -3.26 | -2.60 | 2.30 | 1.78 | 1.91 | 3.59 | 6.34 | 0.69 | 0.95 | 5.06 | 1.76 | 0.49 |
| Tax % | -25.15% | -25.00% | 22.17% | 19.66% | 15.71% | -27.30% | 68.61% | 13.04% | -7.37% | -7.71% | 78.98% | 26.53% |
| Net Profit | -2.44 | -1.95 | 1.80 | 1.44 | 1.61 | 4.57 | 1.99 | 0.60 | 1.02 | 5.44 | 0.37 | 0.36 |
| EPS in Rs | -0.52 | -0.41 | 0.38 | 0.30 | 0.34 | 0.97 | 0.42 | 0.13 | 0.22 | 1.15 | 0.08 | 0.08 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 1 | 76 | 94 | 106 | 133 | 125 | 129 | 105 | 119 | 115 | 112 |
| Expenses | 4 | 2 | 74 | 88 | 102 | 124 | 124 | 133 | 105 | 99 | 101 | 98 |
| Operating Profit | -3 | -1 | 2 | 6 | 4 | 8 | 1 | -5 | -0 | 20 | 14 | 14 |
| OPM % | -1,779% | -56% | 3.2% | 6% | 4.2% | 6% | 0.5% | -3.9% | -0.5% | 17% | 12% | 13% |
| Other Income | 0 | 0 | 1 | 1 | 1 | 2 | 1 | 0 | 2 | 1 | 2 | 1 |
| Interest | 1 | 0 | 1 | 2 | 3 | 3 | 4 | 4 | 5 | 5 | 4 | 3 |
| Depreciation | 0 | 0 | 1 | 1 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 4 |
| Profit before tax | -4 | -1 | 2 | 4 | 1 | 6 | -5 | -12 | -7 | 14 | 8 | 8 |
| Tax % | 0% | -8% | -4% | -1% | -13% | 8% | -26% | -25% | -26% | 29% | 12% | |
| Net Profit | -4 | -1 | 2 | 4 | 1 | 5 | -4 | -9 | -5 | 10 | 7 | 7 |
| EPS in Rs | -5.48 | -1.26 | 2.26 | 2.64 | 0.30 | 1.08 | -0.78 | -1.98 | -1.12 | 2.03 | 1.57 | 1.53 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 90% | -3% | -4% | -7% | ||
| Compounded Profit Growth | 14% | 8% | 43% | -18% | ||
| Stock Price CAGR | 13% | -5% | -5% | -14% | ||
| Return on Equity | % | -1% | 54% | 54% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7 | 7 | 7 | 1 | 1 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | -7 | -11 | -12 | 0 | 4 | 9 | 14 | 10 | 1 | -4 | 5 | 13 |
| Borrowings | 1 | 7 | 14 | 34 | 31 | 34 | 45 | 41 | 53 | 44 | 33 | 35 |
| Other Liabilities | 4 | 1 | 3 | 22 | 29 | 38 | 43 | 54 | 63 | 56 | 68 | 51 |
| Total Liabilities | 5 | 4 | 12 | 58 | 65 | 86 | 107 | 109 | 121 | 100 | 111 | 103 |
| Fixed Assets | 3 | 3 | 7 | 13 | 16 | 18 | 28 | 35 | 34 | 32 | 33 | 37 |
| CWIP | 0 | 0 | 3 | 2 | 2 | 6 | 6 | 0 | 1 | 1 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1 | 1 | 2 | 43 | 48 | 62 | 72 | 74 | 87 | 68 | 78 | 66 |
| Total Assets | 5 | 4 | 12 | 58 | 65 | 86 | 107 | 109 | 121 | 100 | 111 | 103 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 0 | -6 | -1 | -7 | -3 | 0 | 6 | 8 | -7 | 15 | 21 | 11 |
| Cash from Investing Activity | 0 | -0 | -6 | -2 | -2 | -9 | -14 | -1 | -3 | -1 | -5 | -8 |
| Cash from Financing Activity | -0 | 6 | 7 | 10 | 4 | 8 | 8 | -8 | 10 | -13 | -17 | -3 |
| Net Cash Flow | -0 | 0 | 0 | 0 | -0 | 0 | 0 | -0 | -0 | -0 | 0 | 0 |
| Free Cash Flow | 0 | -6 | -7 | -10 | -5 | -9 | -8 | 6 | -10 | 13 | 17 | 3 |
| CFO/OP | -2% | 177% | 85% | -287% | -45% | 5% | 71% | 1,281% | 136% | -3,021% | 105% | 76% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 56 | 173 | 20 | 141 | 113 | 128 | 115 | 88 | 87 | 96 | 113 | 93 |
| Inventory Days | 50 | 319 | 615 | 59 | 83 | 92 | 89 | 146 | 183 | 149 | 178 | 137 |
| Days Payable | 667 | 91 | 511 | 120 | 91 | 121 | 116 | 159 | 177 | 194 | 260 | 220 |
| Cash Conversion Cycle | -560 | 401 | 124 | 80 | 105 | 100 | 88 | 76 | 93 | 51 | 31 | 10 |
| Working Capital Days | -530 | -173 | -1,358 | 48 | 62 | 73 | 53 | 31 | 16 | -30 | -22 | 5 |
| ROCE % | -127% | -188% | -10% | 10% | 16% | 9% | 16% | -2% | -12% | -4% | 42% | 25% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% |
| DIIs | 0.38% | 0.38% | 0.38% | 0.38% | 0.38% | 0.38% | 0.38% | 0.38% | 0.38% | 0.38% | 0.38% | 0.38% |
| Public | 24.67% | 24.66% | 24.67% | 24.68% | 24.67% | 24.68% | 24.67% | 24.68% | 24.68% | 24.68% | 24.68% | 24.68% |
| No. of Shareholders | 12,118 | 12,063 | 12,110 | 12,023 | 12,179 | 12,231 | 12,278 | 12,200 | 12,616 | 12,751 | 12,775 | 12,775 |
Fundamentals
Market Cap₹ 151 Cr.
Current Price₹ 32.0
Stock P/E21.0
Book Value₹ 3.75
ROCE25.1 %
ROE53.7 %
Dividend Yield0.00 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)-7%
Compounded Profit Growth (TTM)-18%
Standalone figures.
Valuation
Market capRs 147 Cr
Enterprise valueRs 181 Cr
P/E (TTM)20.40x
Price to book8.28x
Price to sales1.31x
EV / EBITDA12.08x
EV / EBIT16.63x
EV / sales1.61x
Price to cash flow13.53x
Earnings yield4.90%
P/E, 3-year average17.96x
P/B, 3-year average275.16x
P/E, 5-year average17.96x
P/B, 5-year average173.12x
Profitability
Operating margin (excl. other income)12.42%
Operating margin (incl. other income)13.83%
EBITDA margin13.35%
Pre-tax margin7.37%
Net profit margin6.42%
Net margin, latest quarter1.74%
ROE53.69%
ROCE25.09%
ROA6.93%
ROE, 3-year average19.02%
ROCE, 3-year average20.91%
ROA, 3-year average3.74%
ROE, 5-year average-11.41%
ROCE, 5-year average9.22%
ROA, 5-year average-0.06%
ROIC (approx.)18.45%
Tax rate12.17%
Other income / net worth9.14%
Growth
Sales growth (latest year)-3.40%
Profit growth (latest year)-22.68%
Sales CAGR, 3 years-3.67%
Sales CAGR, 5 years-2.84%
Profit CAGR, 5 years7.82%
Sales growth QoQ-23.82%
Profit growth QoQ-2.70%
Sales growth YoY (latest quarter)-12.13%
Profit growth YoY (latest quarter)-40.00%
Per share
EPS (TTM)Rs 1.52
EPS (latest year)Rs 1.57
EPS (latest quarter)Rs 0.08
EPS, 3-year averageRs 0.83
EPS, 5-year averageRs -0.06
Book value per shareRs 3.75
Sales per shareRs 23.68
Cash flow per shareRs 2.29
Free cash flow per shareRs 0.63
Efficiency
Asset turnover1.11x
Fixed asset turnover3.08x
Inventory turnover2.91x
Inventory days125 days
Debtor days93 days
Debtors turnover3.92x
Creditor days220 days
Cash conversion cycle10 days
Working capital days5 days
Leverage
Total debtRs 35 Cr
Cash and bankRs 1 Cr
Net debtRs 34 Cr
Debt to equity1.96x
Net debt / EBITDA2.27x
Interest coverage4.18x
Owners' fund to total sources17.17%
Debt to assets33.71%
Cash flow
Cash from Operating Activity (latest year)Rs 11 Cr
Cash from Investing Activity (latest year)Rs -8 Cr
Cash from Financing Activity (latest year)Rs -3 Cr
Net Cash Flow (latest year)Rs 0 Cr
Free cash flow (latest year)Rs 3 Cr
FCFE (approx.: FCF + change in debt)Rs 5 Cr
Sales to cash flow10.60x
Statement figures
Net sales (TTM)Rs 112 Cr
Net sales (latest year)Rs 115 Cr
Sales (latest quarter)Rs 21 Cr
Operating profit excl. other income (latest year)Rs 14 Cr
Operating profit (latest quarter)Rs 2 Cr
Other income (TTM)Rs 1 Cr
EBITDA (TTM)Rs 15 Cr
PBDT (TTM)Rs 12 Cr
Profit before tax (TTM)Rs 8 Cr
Tax (latest year)Rs 1 Cr
Net profit (TTM)Rs 7 Cr
Net profit (latest year)Rs 7 Cr
Net profit (latest quarter)Rs 0 Cr
Depreciation (TTM)Rs 4 Cr
Depreciation (latest quarter)Rs 1 Cr
Interest (TTM)Rs 3 Cr
Cost of goods sold (latest year)Rs 76 Cr
Total expenditure (latest year)Rs 101 Cr
Total income (latest year)Rs 116 Cr
Share capitalRs 5 Cr
ReservesRs 13 Cr
Shareholders' fundsRs 18 Cr
Total assetsRs 103 Cr
Net blockRs 37 Cr
Capital work in progressRs 0 Cr
ReceivablesRs 29 Cr
InventoryRs 26 Cr
Other liabilitiesRs 51 Cr
Shares outstanding (crore)4.73
Ownership
Promoter holding74.94% (+0.00 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 20.4 is at the 19th percentile of its own 5.6-year range
(median 35.9, low 12.3, high 160.6).
P/B 8.28 is at the 1th percentile (median 15.87).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | 530313 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +8.1% | -2.8% | +10.9 pts |
| 1 month | +8.8% | -6.8% | +15.6 pts |
| 3 months | -2.4% | -7.6% | +5.2 pts |
| 3 years | -16.1% | +14.2% | -30.3 pts |
| 5 years | -28.5% | +27.9% | -56.4 pts |
Red flags
F-score 5 of 8No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹21 Cr -12.1% vs Jun 2025.
Net profit ₹0 Cr -40.0%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Kimia Biosciences Ltd?
Kimia Biosciences Ltd (530313) has a market capitalisation of Rs 151 Cr. at the 2026-10-01 close.
What is the P/E ratio of Kimia Biosciences Ltd?
Kimia Biosciences Ltd trades at a P/E of 21.0 on trailing twelve-month profit, at the 2026-10-01 close.
What were Kimia Biosciences Ltd's latest quarterly results?
In the Jun 2026 quarter, Kimia Biosciences Ltd sales was Rs 21 Cr (-12.1% vs Jun 2025) and net profit was Rs 0 Cr.